

पेटेंट कार्यालय
शासकीय जर्नल

**OFFICIAL JOURNAL
OF
THE PATENT OFFICE**

निर्गमन सं. 50/2025
ISSUE NO. 50/2025

शुक्रवार
FRIDAY

दिनांक: 12/12/2025
DATE: 12/12/2025

पेटेंट कार्यालय का एक प्रकाशन
PUBLICATION OF THE PATENT OFFICE

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202511104678 A

(19) INDIA

(22) Date of filing of Application :30/10/2025

(43) Publication Date : 12/12/2025

(54) Title of the invention : FORMULATION AND EVALUATION OF SUSTAINED RELEASE TABLETS OF METFORMIN HYDROCHLORIDE

(51) International classification	A61K0009200000, A61K0031155000, A61K0009280000, A61P0003100000, A61K0009000000	(71)Name of Applicant : 1)Dr. Navneet Verma Address of Applicant :Professor, Pharmacy Academy, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, Pin Code: 244102 Uttar Pradesh India 2)Mr. Rajiv Yadav 3)Reema Singh 4)Mohit Chadha 5)Dr. Sandeep Arora 6)Prof. Dr. Shruti Rathore 7)B.Rajgopal 8)V. Nivathra
(31) Priority Document No	:NA	(72)Name of Inventor :
(32) Priority Date	:NA	1)Dr. Navneet Verma
(33) Name of priority country	:NA	2)Mr. Rajiv Yadav
(86) International Application No	:	3)Reema Singh
Filing Date	:01/01/1900	4)Mohit Chadha
(87) International Publication No	: NA	5)Dr. Sandeep Arora
(61) Patent of Addition to Application Number	:NA	6)Prof. Dr. Shruti Rathore
Filing Date	:NA	7)B.Rajgopal
(62) Divisional to Application Number	:NA	8)V. Nivathra
Filing Date	:NA	

(57) Abstract :

ABSTRACT The present invention relates to a sustained release pharmaceutical formulation of Metformin Hydrochloride designed to provide controlled drug delivery over an extended period of twelve to twenty-four hours. The formulation comprises Metformin Hydrochloride as the active pharmaceutical ingredient in combination with hydrophilic polymers including Hydroxypropyl Methylcellulose and Sodium Carboxymethylcellulose, rate-controlling agents, and pharmaceutically acceptable excipients. The sustained release matrix tablets are prepared by direct compression method, ensuring uniform drug distribution and consistent release kinetics. The formulation exhibits zero-order release kinetics, maintaining therapeutic plasma concentrations while minimizing dosing frequency to once or twice daily. This invention addresses the limitations of immediate release formulations including short half-life, frequent dosing requirements, gastrointestinal side effects, and poor patient compliance. The sustained release formulation demonstrates improved bioavailability, reduced side effects, enhanced patient adherence, and superior glycemic control in diabetic patients compared to conventional formulations.

No. of Pages : 18 No. of Claims : 10